Institute of Cancer Research: Royal Cancer Hospital (the)

Richard James Rowland Elliot

Christopher Lord

Dan Niculescu-Duvaz

Alan Ashworth

Trevor Robert Perrior

Rebekah Elisabeth Key

Roderick Alan Porter

Ashley Nicholas Jarvis

Raymond John Boffey

Melanie Jayne Bayford

Stuart Firth-Clark

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc. 

3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use

Growing community of inventors

London, United Kingdom

Richard James Rowland Elliot